 Therapeutics Targeting Editing Enzymes | |
| Company type | Private |
|---|---|
| Industry | |
| Founded | Rochester, New York 2003 |
| Founder | Harold Smith |
| Headquarters | , US |
Area served | Global |
Key people |
|
| Products | Antiviral therapeutic lead compounds |
| Services |
|
Number of employees | 6 |
| Website | oyageninc |
OyaGen is a Rochester, New York-based startup company that is focused on developing treatments for HIV. The company was founded in 2003 by Harold Smith, a professor of biochemistry and biophysics at the University of Rochester.[1][2] OyaGen was founded on research conducted by Smith and Hui Zang, an HIV researcher at Thomas Jefferson University.[1]
- ^ a b Michael Wentzel (12 January 2004). "UR Invests in Anti-HIV Startup". Rochester Chronicle.
- ^ Thomas Adams (16 September 2013). "Henrietta firm OyaGen receives $150,000 investment". Rochester Business Journal. Retrieved 1 June 2014.